Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Temple Sees Sentinel As Important Tool For Confirming And Analyzing Drug Adverse Events

Executive Summary

FDA clinical science expert Robert Temple discusses how the Sentinel project – a drug data monitoring initiative – can support the agency’s postmarket drug safety investigations.

You may also be interested in...



Medicare CED Could Support, Benefit From Surveillance Systems Like FDA’s Sentinel – McClellan

At a May 16 Medicare Evidence Development and Coverage Advisory Committee meeting, former CMS and FDA Chief Mark McClellan advocated salvaging Medicare’s little-used coverage with evidence development policy for medical products.

Unger Takes Over ODE I As Acting Director; Temple To Focus On Clinical Science Role

Mini Sentinel Data Covers 126 Million Patients; FDA Weighing Potential Uses For Drug Industry

With the recent addition of claims data from two major insurance companies, the FDA postmarketing drug safety surveillance pilot project known as Mini Sentinel has already exceeded its statutory goal of gaining access to electronic health care data for 100 million individuals by July 12, 2012.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel